David J Straus MD

PubMed

• 1 citations
  to: Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation.
  Zachary D Epstein-Peterson, Esther Drill, Umut Aypar, Connie Lee Batlevi, Philip Caron
  Haematologica. 2024-08-01
• Matched control analysis suggests that R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared with R-CHOP.
  Kurt S Bantilan, Alexandra N Smith, Matthew J Maurer, Julie Teruya-Feldstein, Matthew J Matasar
  Blood Advances. 2024-05-14
• 1 citations
  Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation.
  Zachary D Epstein-Peterson, Esther Drill, Umut Aypar, Connie Lee Batlevi, Philip Caron
  Haematologica. 2024-04-01

Journal Articles

• CALBG 50604: Risk-Adapted Treatment of Non-Bulky Early Stage Hodgkin Lymphoma Based on Interim PET  
  David J Straus, Heiko Schoder, Bruce D Cheson, John C Grecula, Lale Kostakoglu, Eric D Hsi, Leslie L Popplewell, John P Leonard, Craig H Moskowitz, Brad S Kahl, Jonath..., Blood

Abstracts/Posters

• Genomic Profiling of Mantle Cell Lymphoma Suggests Poor-Risk Profile Is Present at Diagnosis and Does Not Arise By Tumor Evolution
  David J. Straus, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Long-Term Follow-up Confirms Durability of Single-Agent Brentuximab Vedotin As Pre-Transplant Salvage for Classical Hodgkin Lymphoma
  David J. Straus, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Central Nervous System Prophylaxis with High-Dose Intravenous Methotrexate or Intrathecal Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma and High-Risk of ...
  David J. Straus, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Final Results of a Phase II Biomarker-Driven Study of Ruxolitinib in Relapsed and Refractory T-Cell Lymphoma
  David J. Straus, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Contemporary Outcomes in HTLV-1-Associated Adult T-Cell Leukemia/Lymphoma: Single-Institution Experience
  David J. Straus, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Pilot Study of Brentuximab Vedotin Combined with AVD Chemotherapy and Radiotherapy in Patients with Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma
  David J. Straus, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Expectant Management of Extranodal Marginal Zone Lymphoma of Bronchial-Associated Lymphoid Tissue (BALT)
  David J. Straus, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Retrospective Analysis of Gemcitabine and Oxaliplatin (GemOx)-Based Treatment in Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
  David J. Straus, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Phase II, Multicenter Study of High Dose Chemotherapy with Autologous Stem Cell Transplant Followed By Maintenance Therapy with Romidepsin for T-Cell Lymphoma
  David J. Straus, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Brentuximab Vedotin with Chemotherapy for Stage 3/4 Classical Hodgkin Lymphoma (cHL): 4-Year Update of the Echelon-1 Study
  David J. Straus, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• High Complete Response Rate Observed with Second-Line Chemo-Immunotherapy with Pembrolizumab and GVD (Gemcitabine, Vinorelbine, and Liposomal Doxorubicin) in Relapsed ...
  David J. Straus, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Join now to see all

Lectures

• Brentuximab vedotin with chemotherapy for stage 3/4 classical Hodgkin lymphoma: Three-year update of the ECHELON-1 study. 
  2019 ASCO Annual Meeting - 6/1/2019
• Brentuximab Vedotin with Chemotherapy in Adolescents and Young Adults (AYA) with Stage III or IV Hodgkin Lymphoma: A Subgroup Analysis from the Phase 3 Echelon-1 Study 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Improving outcomes with brentuximab vedotin (BV) plus chemotherapy in patients with newly diagnosed advanced stage Hodgkin lymphoma. 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018